Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy

Curr Oncol. 2023 Jan 13;30(1):1146-1150. doi: 10.3390/curroncol30010087.

Abstract

We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype. This case may serve as a paradigmatic example of clonal hematopoietic progression in a patient undergoing CAR-T cell therapy, especially in the context of a TP53-mutated clone.

Keywords: CAR-T cell therapy; clonal evolution; clonal hematopoiesis; therapy-related neoplasia.

Publication types

  • Case Reports

MeSH terms

  • Antigens, CD19
  • Cell- and Tissue-Based Therapy
  • Clonal Hematopoiesis
  • Humans
  • Immunotherapy, Adoptive / methods
  • Male
  • Middle Aged
  • Mutation
  • Receptors, Chimeric Antigen*
  • Remission Induction
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Antigens, CD19
  • Receptors, Chimeric Antigen
  • TP53 protein, human
  • Tumor Suppressor Protein p53

Grants and funding

This research received no external funding.